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Leah M. Ferrucci1, Brenda Cartmel1,2, Annette M. Molinaro2,3, Patricia B. Gordon4, David J. Leffell2,5,
Allen E. Bale2,4,6 and Susan T. Mayne1,2,6
Basal cell carcinoma (BCC) incidence is increasing, particularly among adults under the age of 40 years. Pigment-
related characteristics are associated with BCC in older populations, but epidemiologic studies among younger
individuals and analyses of phenotype–genotype interactions are limited. We examined self-reported
phenotypes and melanocortin 1 receptor gene (MC1R) variants in relation to early-onset BCC. BCC cases
(n¼ 377) and controls with benign skin conditions (n¼ 390) under the age of 40 years were identified through
Yale’s Dermatopathology database. Factors most strongly associated with early-onset BCC were skin reaction to
first summer sun for 1 hour (severe sunburn vs. tan odds ratio (OR)¼ 12.27, 95% confidence interval
(CI)¼ 4.08–36.94) and skin color (very fair vs. olive OR¼ 11.06, 95% CI¼ 5.90–20.74). Individuals with two or more
MC1R non-synonymous variants were 3.59 times (95% CI¼ 2.37–5.43) more likely to have BCC than those
without non-synonymous variants. All host characteristics and MC1R were more strongly associated with
multiple BCC case status (37% of cases) than a single BCC case status. MC1R, number of moles, skin reaction to
first summer sun for 1 hour, and hair and skin color were independently associated with BCC. BCC risk
conferred by MC1R tended to be stronger among those with darker pigment phenotypes, traditionally
considered to be at low risk of skin cancer.
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INTRODUCTION
Basal cell carcinoma (BCC), which accounts for 80% of non-
melanoma skin cancers, is the most common cancer in the
US, with more than two million BCCs diagnosed annually
(Rogers et al., 2010; ACS, 2011). Although BCC is unlikely to
metastasize and is associated with low mortality, morbidity
associated with this disease is quite high. In 1992, among US
Medicare beneficiaries, non-melanoma skin cancer ranked
among the top five most costly cancers to treat (Housman
et al., 2003). Newer data indicate that from 1992 to 2006
in the Medicare population, there was a 77% increase in
the total number of skin cancer–related procedures (93.7%
non-melanoma skin cancer), owing to an increase in the
number of individuals with these malignancies (Rogers et al.,
2010). In recent decades, BCC incidence has increased
(Karagas et al., 1999; Levi et al., 2001; Bath-Hextall et al.,
2007; Birch-Johansen et al., 2010; Doherty et al., 2010;
Arits et al., 2011; Flohil et al., 2011), with notable increases
among adults under the age of 40 years, particularly women
(Christenson et al., 2005; Bath-Hextall et al., 2007; Birch-
Johansen et al., 2010).
UV radiation is the primary environmental etiologic factor
for BCC, yet intrinsic or host factors, including pigment-
related characteristics, are also likely to have a role in
carcinogenesis in conjunction with UV (reviewed in Dessi-
nioti et al., 2010; Madan et al., 2010). Among pigment-related
factors, the melanocortin 1 receptor gene (MC1R), which
encodes a protein that binds melanocyte-stimulating hormone
and regulates skin and hair pigmentation (Valverde et al.,
1995), has received considerable attention and has been
associated with an increased risk of melanoma and BCC
(reviewed in Scherer and Kumar, 2010). Although MC1R
variants are related to light pigmentation phenotypes
(Valverde et al., 1995; Koppula et al., 1997; Smith et al.,
1998; Palmer et al., 2000; Bastiaens et al., 2001; Box et al.,
2001; Kennedy et al., 2001; Dwyer et al., 2004; Kanetsky
et al., 2004; Naysmith et al., 2004; Han et al., 2006), there
seems to be an effect of genotype independent of pheno-
type on both BCC (Bastiaens et al., 2001; Box et al., 2001;
Dwyer et al., 2004; Han et al., 2006; Liboutet et al., 2006;
Scherer et al., 2008) and melanoma (Palmer et al.,
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2000; Kennedy et al., 2001; Dwyer et al., 2004; Landi et al.,
2005; Kanetsky et al., 2010). These findings, in com-
bination with other emerging evidence from epidemiologic,
clinical, and basic science research, indicate that BCC may be
more similar to melanoma than squamous cell carcinoma in
etiology (Dessinioti et al., 2010; Madan et al., 2010).
BCC has been relatively understudied in epidemiologic
research because it is not reported to most cancer registries.
Thus far, two studies provided an intriguing glimpse at risk
factors for early-onset BCC, but these had small sample sizes: 30
cases (Boyd et al., 2002) and 25 cases (Bakos et al., 2011).
Because of the limited understanding of early-onset BCC
etiology, we conducted a case–control study in Connecticut
among individuals under the age of 40 years, investigating
lifestyle, environmental, and genetic factors. The rationale for
this study was multifold and included increasing incidence
among young people, the opportunity to evaluate genetic factors
in a genetically enriched population, the potential for younger
individuals to better recall early-life exposures, and a growing
prevalence of indoor (IARC, 2007) and outdoor tanning.
Here, we describe the design of the Yale Study of Skin
Health in Young People and the associations between host
phenotype characteristics and MC1R in relation to early-
onset BCC. We also evaluated potential variation in the
association between MC1R and BCC by phenotype.
RESULTS
A total of 69% of the 767 participants were women (257
cases, 274 controls). The mean age at skin biopsy in cases
was 35.1 years (SD¼4.6) and 34.7 years (SD¼5.5) in
controls. Among cases, 54.1% (n¼204) had the referent BCC
on the head or neck, followed by 101 (26.8%) with a trunk
BCC, and 72 (19.1%) with a BCC on an extremity.
Approximately 37% (n¼ 140) of cases had two or more
BCCs under the age of 40 years.
All phenotype characteristics and MC1R were significantly
associated with early-onset BCC, with lighter pigment
phenotypes at greater risk (Table 1). The most pronounced
risk factor was skin reaction to first summer sun of the season;
those who experienced severe sunburn and blistering were
12.27 (95% confidence interval (CI)¼4.08–36.94) times more
likely to have BCC than those who turned brown/tanned with
no burning. Skin color was another strong risk factor; indivi-
duals with very fair skin were 11.06 (95% CI¼5.90–20.74)
times more likely to have BCC than those with olive skin. In a
sensitivity analysis, excluding the top three control conditions
one at a time from the control group did not impact risk
estimates for all exposures (data not shown). Controlling for
indoor and outdoor UV exposures did not alter associations for
the characteristics of interest (data not shown).
We detected 35 MC1R variants (Supplementary Table 1
online). Individuals with one MC1R non-synonymous variant
were 93% more likely than those without non-synonymous
variants to have BCC, with a stronger association for
individuals with two or more non-synonymous MC1R
variants (odds ratio (OR)¼ 3.59, 95% CI¼2.37–5.43;
Table 1). Risk was elevated for both ‘‘major’’ and ‘‘minor’’
red hair variants (Table 2).
All host characteristics were associated with both single
and multiple BCC case status, but the magnitude of the risk
estimates for multiple BCC was much greater (Table 1). One
of the most pronounced differences was for skin color.
Although very fair skin as compared with olive skin was
associated with a 6.62 increased risk of single BCC, the OR
for multiple BCC was almost 5.5 times greater (OR¼36.07,
95% CI¼ 8.95–161.94).
Participants with lighter pigment characteristics, less
ability to tan, and more freckles were more likely to have
at least one non-synonymous MC1R variant as compared
with those with darker phenotypes (Supplementary Table 2
online).
In the mutually adjusted model, hair and skin color,
MC1R, moles, and skin reaction to first summer sun were
independently associated with BCC (Table 3). Very fair
skin was associated with a 4.48-fold independent increased
risk of BCC compared with olive skin (OR¼4.48, 95%
CI¼2.21–9.09), and individuals with two or more non-
synonymous variants had a 91% independent increased
risk compared with those with no variants (OR¼ 1.91, 95%
CI¼1.20–3.03).
Although there was no evidence of significant interactions
between phenotypes and MC1R in relation to BCC risk, we
observed some general patterns in risk across strata (Table 4).
The association betweenMC1R and BCC was stronger among
individuals with darker phenotypes, including darker eye and
skin color, fewer moles and freckles, and tanning rather than
burning with sun exposure.
DISCUSSION
In this case–control study of early-onset BCC, host phenotype
characteristics of lighter pigmentation and inability to tan, as
well asMC1R, were independently associated with increased
disease risk. To our knowledge, a large-scale epidemiologic
study focused exclusively on BCC among young adults
has not been previously reported. In our unique population,
the magnitudes of risk associated with phenotype character-
istics often associated with BCC were generally magni-
fied as compared with studies in older individuals (Hogan
et al., 1989; Vitasa et al., 1990; Maia et al., 1995; Zanetti
et al., 1996; Naldi et al., 2000; Dessinioti et al., 2010;
Kiiski et al., 2010). Although BCC is relatively rare in young
people, 37% of our cases had two or more BCCs under the
age of 40 years, and the association with each of our
exposures was much stronger for these cases.
Our finding of a nearly 2-fold increase in BCC risk for one
non-synonymous MC1R variant and a 3.6-fold increase for
two non-synonymous variants is in agreement with other
BCC studies (Bastiaens et al., 2001; Box et al., 2001; Dwyer
et al., 2004; Han et al., 2006; Scherer et al., 2008).
Nevertheless, as we hypothesized, the magnitude of risk we
observed was greater than in studies of older adults, where
risk estimates have been less than or equal to 2.6 (Bastiaens
et al., 2001; Box et al., 2001; Dwyer et al., 2004; Han et al.,
2006; Scherer et al., 2008). It is noteworthy that one small
case–control study with a heterogeneous case group enrolled
on the basis of having either familial BCC, multiple BCC,
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Table 1. ORs and 95% CIs for association between host characteristics and MC1R and BCC in the Yale Study of
Skin Health
Characteristic
Cases, N=377
N1 (%)
Controls, N=390
N1 (%)
All BCCs
OR2 (95% CI)
Single BCC, 237 cases
OR2 (95% CI)
Multiple BCC, 140
cases OR2 (95% CI)
Eye color
Brown 86 (22.8) 154 (39.5) 1.00 1.00 1.00
Hazel 65 (17.2) 72 (18.5) 1.76 (1.14–2.72) 1.66 (1.02–2.71 ) 2.15 (1.08–4.27)
Green 47 (12.5) 38 (9.7) 2.34 (1.40–3.91) 1.94 (1.08–3.48) 3.43 (1.64–7.17)
Blue/gray 179 (47.5) 126 (32.3) 2.60 (1.83–3.72) 1.81 (1.21–2.71) 5.20 (3.00–9.00)
Hair color
Black/dark brown 101 (26.9) 161 (41.3) 1.00 1.00 1.00
Light brown 136 (36.2) 155 (39.7) 1.42 (1.01–2.01) 1.28 (0.86–1.89) 1.84 (1.09–3.10)
Blonde/fair 100 (26.6) 63 (16.2) 2.66 (1.76–4.01) 2.15 (1.35–3.44) 4.07 (2.29–7.22)
Red 39 (10.4) 11 (2.8) 6.38 (3.08–13.22) 3.74 (1.59–8.80) 14.27 (6.11–33.32)
Skin color
Olive 15 (4.0) 77 (19.7) 1.00 1.00 1.00
Fair 213 (56.5) 236 (60.5) 4.78 (2.65–8.62) 3.74 (1.98–7.04) 11.39 (2.71–47.78)
Very fair 149 (39.5) 77 (19.7) 11.06 (5.90–20.74) 6.62 (3.34–13.10) 36.07 (8.95–161.94)
Skin reaction with first summer sun exposure
Turn brown, no sunburn 6 (1.6) 31 (8.0) 1.00 1.00 1.00
Mild sunburn followed by tan 142 (37.7) 200 (51.4) 3.65 (1.47–9.07) 3.34 (1.24–9.02) 5.32 (0.70–40.51)
Painful sunburn peeling 199 (52.8) 144 (37.0) 7.50 (3.00–18.72) 5.10 (1.87–13.89) 18.35 (2.44–138.16)
Severe sunburn blistering 30 (8.0) 14 (3.6) 12.27 (4.08–36.94) 7.34 (2.11–25.50) 36.72 (4.36–309.37)
Skin reaction with prolonged sun exposure
Very brown, deeply tanned 39 (10.3) 71 (18.2) 1.00 1.00 1.00
Moderately tanned 169 (44.8) 223 (57.2) 1.38 (0.89–2.16) 1.10 (0.67–1.80) 2.42 (1.10–5.32)
Mildly tanned peeling tendency 123 (32.6) 78 (20.0) 2.96 (1.81–4.85) 1.97 (1.14–3.42) 6.24 (2.76–14.11)
Freckled, no suntan 46 (12.2) 18 (4.6) 4.89 (2.47–9.69) 3.59 (1.67–7.69) 10.19 (3.80–27.36)
MC1R non-synonymous variants
0 Variants 65 (17.3) 131 (34.2) 1.00 1.00 1.00
1 Variant 173 (46.0) 175 (45.7) 1.93 (1.33–2.80) 1.76 (1.15–2.69) 2.35 (1.33–4.14)
X2 Variants 138 (36.7) 77 (20.1) 3.59 (2.37–5.43) 2.93 (1.82–4.71) 5.15 (2.84–9.32)
Moles X5mm on back
None 173 (46.1) 209 (53.6) 1.00 1.00 1.00
1–4 137 (36.5) 146 (37.4) 1.17 (0.85–1.60) 1.13 (0.79–1.61) 1.27 (0.81–1.98)
5–9 42 (11.2) 24 (6.2) 2.36 (1.36–4.12) 1.62 (0.83–3.17) 3.69 (1.90–7.17)
10 or more 23 (6.1) 11 (2.8) 3.00 (1.39–6.48) 2.21 (0.86–5.64) 4.43 (1.84–10.67)
Freckles on face
None 78 (20.7) 139 (35.6) 1.00 1.00 1.00
Very few 82 (21.8) 112 (28.7) 1.38 (0.92–2.07) 1.31 (0.83–2.06) 1.74 (0.90–3.37)
Few 123 (32.6) 93 (23.9) 2.39 (1.61–3.55) 1.80 (1.15–2.81) 4.39 (2.38–8.08)
Some 74 (19.6) 36 (9.2) 3.99 (2.42–6.58) 2.96 (1.68–5.20) 7.64 (3.78–15.46)
Many 20 (5.3) 10 (2.6) 3.84 (1.69–8.76) 1.50 (0.50–4.49) 11.63 (4.43–30.54)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; MC1R, melanocortin 1 receptor; OR, odds ratio.
1May not sum to total due to missing data.
2Adjusted for frequency-matching study variables: age at diagnosis (continuous), body site (head, extremity, trunk), and gender.
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BCC with another cancer, or BCC before the age of 40 years
observed a 7-fold increased risk of BCC with two MC1R
variants (Liboutet et al., 2006). Similar to our findings,
MC1R variants have been associated with lighter pigment
phenotypes in numerous studies (Valverde et al., 1995;
Koppula et al., 1997; Smith et al., 1998; Palmer et al.,
2000; Bastiaens et al., 2001; Box et al., 2001; Kennedy et al.,
2001; Dwyer et al., 2004; Kanetsky et al., 2004; Naysmith
et al., 2004; Han et al., 2006).
The independent associations with early-onset BCC for
MC1R, hair and skin color, moles, and skin reaction are in
line with several studies of BCC (Bastiaens et al., 2001; Box
et al., 2001; Dwyer et al., 2004; Han et al., 2006; Liboutet
et al., 2006; Scherer et al., 2008) and melanoma (Palmer
et al., 2000; Kennedy et al., 2001; Dwyer et al., 2004; Landi
et al., 2005; Kanetsky et al., 2010). The fact that MC1R
remained an independent risk factor suggests that variants in
this gene contribute to BCC pathogenesis through other
mechanisms in addition to pigmentation. As a potential
tumor initiator, impairment of MC1R function leads to
synthesis of pheomelanin, which acts as a free-radical
generator and may cause oxidative DNA damage over and
above the UVB-induced damage typically associated with
sunlight exposure to fair skin (Scherer and Kumar, 2010).
Furthermore, mouse studies show an effect of MC1R
genotype on production of premalignant clones in the
absence of any melanin pigment, suggesting a mechanism
separate from pigment modulation (Robinson et al., 2010). A
role in tumor progression through regulation of cytokines and
their associated receptors, such as NF-kB, has been suggested
(Eves et al., 2003; Getting, 2006). There is a complex
interplay between NF-kB regulation and the ability of tumor
cells to escape immune surveillance and invade surrounding
tissues.
The association of pigment phenotypes independent of
MC1R genotype points toward the involvement of other
pigment-related genes in BCC risk. TYR, ASIP, and SLC45A2
have been identified in other BCC studies (Gudbjartsson
et al., 2008; Nan et al., 2009; Stacey et al., 2009; Scherer and
Kumar, 2010).
We found that MC1R was more strongly associated with
early-onset BCC among those with darker phenotypes.
Several other BCC studies have evaluated this genotype–phe-
notype interaction, but results have been inconsistent. One
study observed no clear variation in the association of MC1R
and BCC risk by hair or skin color (Han et al., 2006), whereas
others found an increased risk in those with darker hair and
skin, but opposite patterns for eye color (Liboutet et al.,
2006), or suggestive increased risk among individuals with
the lightest skin (Bastiaens et al., 2001; Scherer et al., 2008).
One study of BCC (Dwyer et al., 2004) and several of
melanoma (Ichii-Jones et al., 1998; Palmer et al., 2000;
Dwyer et al., 2004; Landi et al., 2005; Kanetsky et al., 2010)
had findings similar to ours.
Our findings, in conjunction with research in melanoma,
may have applicability in primary prevention. Among
participants with the darkest pigment phenotypes, the
estimated etiologic fractions for carrying two or more non-
synonymous MC1R variants ranged from a low of 12%
among individuals with no freckles on the face to a high of
28% among individuals with brown eyes. Because people
with darker phenotypes are also at risk of skin cancer, sun
protection interventions may need to be broadened to
include these individuals who would otherwise consider
themselves at low risk.
Our study had several strengths including extensive self-
report phenotype data from a face-to-face interview and
MC1R sequencing for nearly all participants. Importantly, the
laboratory was blinded to case–control status, and inter-
viewers were blinded to case–control status until the end of
the interview. Using a centralized dermatopathology facility
serving many dermatologists in Connecticut enabled us to
identify controls most likely to constitute the source popula-
tion of our cases; that is, young people who see a
dermatologist for a skin lesion. Because our controls had
undergone a skin biopsy, this may have reduced differential
reporting by case status, as our controls may have been more
sensitive to exposures concerning skin health than general
population controls. Our results were robust in sensitivity
analyses removing specific control conditions, indicating that
associations were not driven by inclusion of one benign
condition.
As in any case–control study, selection bias is a potential
concern. Another potential limitation is related to possible
misclassification within participant self-reported measures of
Table 2. Alternate classifications of MC1R variants in
relation to BCC in the Yale Study of Skin Health.
Referent group for all variables is individuals with no
non-synonymous variants
Characteristic
Cases/
controls OR1 (95% CI)
No non-synonymous variants 65/131 1.00
MC1R ‘‘major’’ red hair variants2
1 Variant 158/108 2.88 (1.94–4.27)
X2 Variants 31/11 5.85 (2.73–12.54)
MC1R alternate ‘‘major’’ red hair
variants3
1 Variant 147/95 2.97 (1.98–4.44)
X2 Variants 20/8 4.95 (2.04–12.00)
MC1R ‘‘minor’’ red hair variants4
1 Variant 147/129 2.20 (1.55–3.11)
X2 Variants 34/30 3.09 (1.88–5.07)
1 ‘‘Major’’2 and 1 ‘‘minor’’ red hair
variant
63/31 3.95 (2.31–6.76)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; MC1R,
melanocortin 1 receptor; OR, odds ratio.
1Adjusted for age at diagnosis (continuous), body site (head, extremity,
trunk), and gender.
2Includes D84E, R142H, R151C, I155T, R160W, and D294H.
3Includes R151C, R160W, and D294H.
4Includes V60L, V92M, and R163Q.
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phenotype, as we did not have more objective measures of
pigment characteristics, such as clinician assessment or
spectroscopy, but this is most likely to be non-differential.
Finally, although controls were seen by a dermatologist for a
benign skin condition, we did not know whether a complete
skin examination was performed. Therefore, controls could
have possibly had a BCC; however, the likelihood of this is
low in our young sample.
In summary, several host phenotype characteristics and
MC1R were strongly and independently related to early-onset
BCC. In this young population, the associations between the
exposures of interest and disease risk were more pronounced
for multiple BCC, and the relationship between MC1R
and BCC was stronger among individuals with darker
pigmentation phenotypes. Even persons with darker pigment
Table 3. Mutually adjusted ORs and 95% CIs for the
most parsimonious model of the association between
host characteristics, MC1R, and BCC in the Yale Study
of Skin Health
Characteristic
Cases/
controls
Mutually
adjusted
OR1 (95% CI)
Hair color
Black/dark brown 99/157 1.00
Light brown 135/151 1.31 (0.78–1.64)
Blonde/fair 100/63 1.63 (1.04–2.53)
Red 39/11 2.74 (1.23–6.09)
Skin color
Olive 15/74 1.00
Fair 211/232 2.75 (1.46–5.18)
Very fair 147/76 4.48 (2.21–9.09)
MC1R non-synonymous variants
0 Variants 65/130 1.00
1 Variant 172/175 1.41 (0.95–2.11)
X2 Variants 136/77 1.91 (1.20–3.03)
Moles X5mm on back
None 172/204 1.00
1–4 136/145 1.03 (0.73–1.44)
5–9 42/22 1.93 (1.05–3.52)
10 or more 23/11 2.19 (0.98–4.90)
Skin reaction with first summer sun
exposure
Turn brown, no sunburn 6/31 1.00
Mild sunburn followed by tan 141/196 1.91 (0.73–5.03)
Painful sunburn peeling 196/142 2.43 (0.90–6.58)
Severe sunburn blistering 30/13 3.68 (1.11–12.23)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; MC1R,
melanocortin 1 receptor; OR, odds ratio.
1Adjusted for age at diagnosis (continuous), body site (head, extremity,
trunk), gender, and all other characteristics in table.
Table 4. MC1R non-synonymous variants and BCC
risk stratified by host characteristics in the Yale Study
of Skin Health
Characteristic
MC1R
variants
Cases/
controls OR1 (95% CI)
P for
interaction2
Eye color 0.557
Brown 0 17/56 1.00
1 38/71 1.64 (0.82–3.29)
X2 31/23 4.37 (1.99–9.56)
Hazel/green 0 17/34 1.00
1 52/48 2.06 (1.01–4.20)
X2 42/26 2.99 (1.38–6.47)
Blue/gray 0 31/41 1.00
1 83/56 1.95 (1.08–3.53)
X2 65/28 3.25 (1.67–6.35)
Hair color 0.670
Black/dark brown 0 23/62 1.00
1 55/72 1.94 (1.05–3.58)
X2 22/23 2.62 (1.20–5.73)
Light brown 0 24/53 1.00
1 66/69 2.00 (1.09–3.67)
X2 46/30 3.12 (1.57–6.19)
Blonde/fair/red 0 18/16 1.00
1 51/34 1.23 (0.54–2.80)
X2 70/24 2.44 (1.05–5.65)
Skin color 0.364
Olive/fair 0 47/120 1.00
1 111/132 2.04 (1.32–3.14)
X2 69/55 3.38 (2.04–5.59)
Very fair 0 18/11 1.00
1 62/43 0.94 (0.39–2.25)
X2 69/22 1.81 (0.72–4.52)
Skin reaction to first
summer sun exposure
0.851
Turn brown, no
burn/mild burn then
tan
0 38/96 1.00
1 69/98 1.64 (1.00–2.71)
X2 41/33 3.04 (1.64–5.61)
Painful burn
peeling/severe burn
blistering
0 27/34 1.00
1 104/77 1.63 (0.90–2.96)
X2 97/44 2.64 (1.41–4.96)
Skin reaction to
prolonged sun
exposure
0.299
Very brown/
moderately tanned
0 46/115 1.00
1 102/129 1.92 (1.24–2.99)
X2 59/45 3.49 (2.04–5.95)
Table 4 continued on the following page
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phenotypes, traditionally considered to be at low risk of skin
cancer, were at substantial risk of early-onset BCC if they had
MC1R variants. To our knowledge, a large-scale epidemio-
logic investigation of these characteristics in relation to early-
onset BCC is previously unreported, and thus our results need
confirmation in other populations.
MATERIALS AND METHODS
Study design
The Yale Study of Skin Health in Young People was conducted in
Connecticut between July 2007 and December 2010. BCC cases
diagnosed between 1 July 2006 and 30 September 2010 were
identified through Yale University’s Dermatopathology database.
Approximately two-thirds of the dermatologists in Connecticut send
their patients’ biopsied tissue to Yale for dermatopathologic
evaluation. Potential controls were randomly sampled from indivi-
duals in the database with a variety of minor benign skin conditions.
To be eligible for the study, participants had to fulfill the following
criteria: be o40 years of age at the time of skin biopsy, reside in
Connecticut, speak English, and themselves (or appropriate guardian
for decisionally impaired individuals and those under age 18) be
mentally and physically capable of completing study components.
Yale University’s Institutional Review Board approved the study, and
participants (or guardians) provided written informed consent. The
study was conducted in accordance with the Declaration of Helsinki
Principles.
Potential participants were mailed a letter and study brochure.
One of two study interviewers then contacted individuals by
telephone and invited them to participate in the study. If the
telephone number was not working (disconnected, wrong number,
no number listed), another letter was mailed asking for updated
contact information via telephone or mail. If the telephone number
and mailing address were incorrect, updated contact information
was sought periodically.
Among the 665 potentially eligible BCC cases identified during
the study period, 17 (2.6%) were determined ineligible upon initial
contact: 14 moved out of the state and 3 could not complete all
study components (2 non-English speakers, 1 severe illness). Of the
remaining 648 individuals, 114 (17.6%) could not be contacted
directly (no telephone number, non-working telephone number,
only spoke to other person in household, left message only). Among
the 534 cases we were able to directly reach and determine full
eligibility, 145 (27.2%) refused to participate, resulting in 389
enrolled cases (participation rate¼ 72.8%).
Cases were classified into single (only one BCC) or multiple (two
or more BCCs) BCC under the age of 40 years based on participant
self-report and searching the Yale Dermatopathology database
(records from 1990 on). A total of 242 (62.2%) cases had one BCC
in the database and did not self-report a prior BCC, and 120 (30.9%)
cases had two or more BCCs in the database. The remaining 27
(6.9%) cases had one BCC in the database, but self-reported a prior
BCC; these individuals were categorized as multiple cases, as this
did not significantly alter risk estimates.
To determine control eligibility, two dermatologists reviewed
skin conditions diagnosed during a 1-year period in persons under
the age of 40 years in the Yale Dermatopathology database. A variety
of diagnoses were determined ineligible for sampling, including
skin cancers/precancers (e.g., melanoma, squamous cell carcinoma,
T-cell lymphomas, actinic keratoses), potentially UV-related benign
conditions (e.g., solar lentigo, abnormal nevus), erythematous
conditions associated with photosensitivity or aggravated by UV
exposure (e.g., lumps erythematous, erythema multiforme, rosacea),
dermal conditions treated with UV therapy (e.g., psoriasis), and
pigment disorders (e.g., vitiligo).
Randomly sampled controls were frequency matched to BCC
cases on age at biopsy (5-year age groups), gender, and biopsy site
(head/neck, trunk, extremity). Among the 1,102 potentially eligible
controls, 60 (5.4%) were found ineligible upon initial contact (39
moved out of state, 10 were non-English speakers, 2 did not recall
having a skin biopsy, 1 was hearing impaired, and 1 was
hospitalized) or during the interview (7 self-reported a BCC). Of the
remaining 1,042 individuals, 288 (27.6%) could not be contacted
directly. Among the 754 potential controls we could directly reach
and determine full eligibility, 296 (39.3%) refused to participate and
458 controls were enrolled (participation rate¼ 60.7%). Controls had
Table 4. Continued
Characteristic
MC1R
variants
Cases/
controls OR1 (95% CI)
P for
interaction2
Mildly tanned
peeling/freckled,
no tan
0 19/16 1.00
1 71/46 1.12 (0.51–2.45)
X2 79/32 1.81 (0.81–4.03)
Moles X5mm on
back
0.496
None 0 28/74 1.00
1 85/91 2.54 (1.48–4.35)
X2 59/39 4.05 (2.20–7.47)
1–4 0 27/52 1.00
1 55/61 1.68 (0.92–3.07)
X2 55/33 3.31 (1.72–6.36)
X5 0 10/5 1.00
1 33/23 0.51 (0.14–1.89)
X2 22/5 2.26 (0.49–10.46)
Freckles on face 0.723
None 0 28/68 1.00
1 38/60 1.55 (0.83–2.92)
X2 12/8 4.33 (1.54–12.15)
Very few 0 18/38 1.00
1 38/50 1.73 (0.83–3.59)
X2 26/21 2.44 (1.06–5.61)
Few/some/many 0 19/25 1.00
1 97/65 1.88 (0.95–3.75)
X2 100/48 2.55 (1.26–5.15)
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; MC1R,
melanocortin 1 receptor; OR, odds ratio.
1Adjusted for age at diagnosis (continuous), body site (head, extremity,
trunk), and gender.
2Based on inclusion of cross-product term in multivariate model.
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a variety of benign skin conditions. The three most common were
cyst (16.4%), seborrheic keratosis (16.2%), and wart (11.4%). All
other conditions were present in o10% of controls.
Participants completed an in-person face-to-face interview
during which interviewers obtained information on sociodemo-
graphics, UV exposure (solar and artificial), personal and family
medical history, and host phenotype characteristics, including self-
reported eye color, skin color (inner upper arm), hair color (natural
color), skin reaction to strong sunlight for the first time in the summer
for 1 hour without sunscreen, skin reaction after repeated and
prolonged exposure to sunlight, amount of freckles on the face
(selected from a range of images), and number of moles on the back
X5mm (using clear acetate size template), using a structured
questionnaire. Interviewers were blinded to case–control status until
the end of the interview, when personal history of cancer, including
BCC, was queried.
Participants also completed several mailed self-administered
questionnaires (residence history, outdoor jobs, attitudes toward
sunless, outdoor, and indoor tanning). Interviewers collected
buccal cells from 98.9% of participants using Oragene DNA 2ml
saliva collection kits (DNA Genotek, Ontario, Canada; http://
www.dnagenotek.com/index.html) at the end of the interview
following the manufacturer’s protocol, including rinsing the mouth
with drinking water and then waiting for 5 minutes before
collection.
MC1R sequencing and variant classification
Oragene kits were stored at room temperature until processed. DNA
was isolated based on the manufacturer’s protocol. Laboratory
personnel were blinded to case–control status.
The MC1R gene was PCR amplified as a single 1.3 kbp fragment.
Each 25ml PCR reaction contained 25–50ng of DNA; 200mmol l1
deoxyribonucleotide triphosphates; 5mmol l1 of each primer,
50-ACTAAGCAGGACACCTGGAG-30 and 50-TCTTTAGGAGCCTGA
GGTTG-30; PC2 buffer (50mM Tris-HCl, pH 9.1, 16mM ammonium
sulfate, 3.5mM MgCl2, and 150mgml
1 BSA; Ab Peptides, St Louis,
MO); 0.25mmol l1 spermidine; 0.125U of Taq DNA polymerase
(Amplitaq, Roche, Basel, Switzerland); and 0.125U of Taq Extender
(Stratagene, Santa Clara, CA). PCR was performed with an initial
denaturation for 2 minutes at 97 1C, followed by 35 cycles of
denaturation at 96 1C for 30 seconds, annealing at 66 1C for
30 seconds, and extension for 1 minute at 72 1C, and a final extension
at 72 1C for 5 minutes. PCR products were size fractionated on a 1.5%
GPG/LETM (American Bioanalytical, Natick, MA) agarose gel, stained
with ethidium bromide, and photographed under UV light in order to
confirm the presence of the correct PCR fragment.
PCR products were sequenced bidirectionally. A volume of 5ml
of the PCR products was treated with 20U Exonuclease I (E. coli;
New England BioLabs, Ipswich, MA) and 2U Shrimp Alkaline
Phosphatase (USB, Santa Clara, CA). Either 0.4 mmol l1 of the
forward primer, 50-ACTAAGCAGGACACCTGGAG-30, or the reverse
primer, 50-GGTCACACAGGAACCAGACC-30, was added. The
sequencing was carried out at Yale University’s W.M. Keck Facility
using Applied Biosystems 3730 capillary instruments (Applied
Biosystems, Carlsbad, CA). The sequencing reactions used fluores-
cently labeled dideoxynucleotides (Big Dye Terminators, Applied
Biosystems) and Taq FS DNA polymerase in a thermal cycling
protocol. The sequence was analyzed using Sequencher 4.9 (Gene
Codes, Ann Arbor, MI) comparing the query sequence to the
standard sequence with no variants in MC1R (NM_002386.3).
MC1R variants were classified into synonymous and non-
synonymous variants. Non-synonymous variants were grouped into
‘‘major’’ and ‘‘minor’’ red hair variants (Valverde et al., 1995; Box
et al., 1997; Kanetsky et al., 2004). We then calculated the number
of total non-synonymous variants within the MC1R coding region.
Statistical analysis
Analyses were limited to non-Hispanic Whites: 380 (97.7%) cases
and 390 (85.2%) controls. Three BCC cases with Gorlin Syndrome,
which predisposes individuals to multiple BCCs early in life (Gorlin
and Goltz, 1960), were also excluded. Our analytic population
consisted of 767 individuals (377 cases, 390 controls); three cases
and three controls were under the age of 18 years at enrollment.
Phenotype characteristics andMC1R (count of all non-synonymous
variants within the gene, 0, 1,X2 variants) were treated as categorical
variables. We calculated ORs and 95% CIs using multivariate logistic
regression for all cases. Analyses were then restricted to cases with
only one BCC (n¼ 237) and then cases with two or more BCCs
(n¼ 140). We determined independent relationships using backward
stepwise selection, retaining only exposures statistically significant at
a¼ 0.05, as well as gender, age, and body site. Phenotype–genotype
interactions were tested with cross-product terms. Analyses were
conducted using SAS Version 9.2 (SAS Institute, Cary, NC).
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